Abstract
Background: Sairei-to is a herbal prescription originating from traditional Chinese medicine. We conducted an experimental study on rat peritoneal fibrosis to clarify the suppressive mechanisms of sairei-to. Methods: Wistar rats were intraperitoneally injected with chlorhexidine gluconate (CG) every day. Peritoneal specimens were collected after 28 days of CG injection and oral administration of sairei-to. Macrophage infiltration, extracellular matrix accumulation, and angiogenesis were evaluated by immunostaining for ED-1, fibronectin, and CD-31, respectively. To observe oxidative stress in the tissue, 4-hydroxy-2-noneal (HNE) accumulation and plasma levels of superoxide dismutase (SOD) activity were detected. As a candidate of antioxidative components in sairei-to, plasma levels of baicalin were determined by high-performance liquid chromatography. Results: Compared with the disease control group, serum total protein levels were significantly recovered in the sairei-to treatment group. Thickness of the submesothelial compact zone, trichrome-stained area, ED-1-positive cells, fibronectin-staining area, and HNE accumulation were suppressed in the treatment group. Concurrently, decreased plasma levels of SOD activity were recovered by sairei-to treatment. Increased CD-31-positive vessel number and area were also suppressed in the sairei-to group. Baicalin was detected in the plasma samples of the sairei-to group at 0.29 ± 0.11 µg/ml (mean±SEM). Conclusion: These results suggest that sairei-to ameliorates peritoneal fibrosis, partly through suppressing oxidative stress and macrophage infiltration.
Journal Section:
Original Paper
References
1.
Burkart JM: Peritoneal dialysis; in Brenner BM (ed): Brenner and Rector’s The Kidney (vol 2), ed 6. Philadelphia, Saunders, 2000, pp 2454–2517.
2.
Afthentopoulos IE, Passadakis P, Oreopoulos DG: Sclerosing peritonitis in continuous ambulatory peritoneal dialysis patients: one center’s experience and review of the literature. Adv Ren Replace Ther 1998;5:157–167.
[PubMed]
3.
Gandhi VC, Humayun HM, Ing TS, Daugirdas JT, Jablokow VR, Iwatsuki S, Geis WP, Hano JE: Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients. Arch Intern Med 1980;140:1201–1203.
[PubMed]
4.
Coles GA, Topley N: Long-term peritoneal membrane changes. Adv Ren Replace Ther 2000;7:289–301.
[PubMed]
5.
Imai H, Nakamoto H, Fucshima R, Yamanouchi Y, Ishida Y, Suzuki H: Glucocorticoid protects against the development of encapsulating peritoneal sclerosis on peritoneal dialysis. Adv Perit Dial 2002;18:124–130.
[PubMed]
6.
Kawanishi H, Watanabe H, Moriishi M, Tsuchiya S: Successful surgical management of encapsulating peritoneal sclerosis. Perit Dial Int 2005;25(suppl 4):S39–S47.
[PubMed]
7.
Honda K, Oda H: Pathology of encapsulating peritoneal sclerosis. Perit Dial Int 2005;25(suppl 4):S19–S29.
[PubMed]
8.
Io H, Hamada C, Ro Y, Ito Y, Hirahara I, Tomino Y: Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int 2004;65:1927–1936.
[PubMed]
9.
Mitani K, Nagai Y, Oneyama T: Treatment for thirsty and nausea; in Yakazu K, Matsushita K (eds): Japanese Traditional Medicine. Tokyo, Midori Shobo, 1999, pp 758–759, 815–818 (in Japanese).
10.
Yoshikawa N, Ito H, Sakai T, Takekoshi Y, Honda M, Awazu M, Ito K, Iitaka K, Koitabashi Y, Yamaoka K, Nakagawa K, Nakamura H, Matsuyama S, Seino Y, Takeda N, Hattori S, Ninomiya M: A prospective controlled study of sairei-to in childhood IgA nephropathy with focal/minimal mesangial proliferation. Nippon Jinzo Gakkai Shi 1997;39:503–506.
[PubMed]
11.
Asano T, Fujii Y, Numao N, Kageyama Y, Kihara K: The efficiency of sairei-to for retroperitoneal fibrosis: two case reports. Hinyokika Kiyo 2006;52:543–547.
[PubMed]
12.
Li P, Kawachi H, Morioka T, Orikasa M, Oite T, Shi ZS, Shimizu F: Suppressive effects of sairei-to on monoclonal antibody 1-22-3-induced glomerulonephritis: analysis of effective components. Pathol Int 1997;47:430–435.
[PubMed]
13.
Ono T, Liu N, Makino T, Nogaki F, Muso E, Honda G, Kita T: Suppressive mechanisms of sairei-to on mesangial matrix expansion in rat mesangioproliferative glomerulonephritis. Nephron Exp Nephrol 2005;100:e132–e142.
[PubMed]
14.
Suga H, Teraoka S, Ota K, Komemushi S, Furutani S, Yamauchi S, Margolin S: Preventive effect of pirfenidone against experimental sclerosing peritonitis on rats. Exp Toxic Pathol 1995;47:287–291.
[PubMed]
15.
Ishii Y, Sawada T, Shimizu A, Tojimbara T, Nakajima I, Fuchinoue S, Teraoka S: An experimental sclerosing encapsulating peritonitis model in mice. Nephrol Dial Transplant 2001;16:1262–1266.
[PubMed]
16.
Kimuya Y, Kubo M, Tani T, Arichi S, Okuda H: Studies on scutellariae radix. IV. Effects on lipid peroxidation in rat liver. Chem Pharm Bull (Tokyo) 1981;29:2610–2617.
[PubMed]
17.
Liu JJ, Huang TS, Cheng WF, Lu FJ: Baicalein and baicalin are potent inhibitors of angiogenesis: inhibition of endothelial cell proliferation, migration and differentiation. Int J Cancer 2003;106:559–565.
[PubMed]
18.
Nishino T, Miyazaki M, Abe K, Furusu A, Mishima Y, Harada T, Taguchi T, Koji T, Kohno S: Enhanced expression of heat shock protein 47 (HSP47) in a rat model of peritoneal fibrosis. Perit Dial Int 2003;23:14–22.
[PubMed]
19.
Liu N, Makino T, Nogaki F, Kusano H, Suyama K, Muso E, et al: Coagulation in the mesangial area promotes extracellular matrix accumulation through factor V expression in MsPGN in rats. Am J Physiol Renal Physiol 2004;287:F612–F620.
[PubMed]
20.
Saito H, Kitamoto M, Kato K, Liu N, Kitamura H, Uemura K, Nogaki F, Takeda T, Mori N, Ono T: Tissue factor and factor V involvement in rat peritoneal fibrosis. Perit Dial Int 2009;29:340–351.
[PubMed]
21.
Burns WC, Twigg SM, Forbes JM, Pete J, Tikellis C, Thallas-Bonke V, Thomas MC, Cooper ME, Kantharidis P: Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol 2006;17:2484–2494.
[PubMed]
22.
Zhang L, Lin G, Zuo Z: High-performance liquid chromatographic method for simultaneous determination of baicalein and baicalein 7-glucuronide in rat plasma. J Pharm Biomed Anal 2004;36:637–641.
[PubMed]
23.
Yoshio Y, Miyazaki M, Abe K, Nishino T, Furusu A, Mizuta Y, Harada T, Ozono Y, Koji T, Kohno S: Antisense oligonucleotides against collagen-binding stress protein HSP47 suppress peritoneal fibrosis in rats. Kidney Int 2003;64:887–896.
[PubMed]
24.
Miyata T, Horie K, Ueda Y, Fujita Y, Izuhara Y, Hirano H, Uchida K, Saito A, van Ypersele de Strihou C, Kurokawa K: Advanced glycation and lipidoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int 2000;58:425–435.
[PubMed]
25.
Kim YG, Lee CK, Byeon JS, Myung SJ, Oh JS, Nah SS, Moon HB, Yoo B: Serum cholesterol in idiopathic and lupus-related protein-losing enteropathy. Lupus 2008;17:575–579.
[PubMed]
26.
Lee HB, Yu MR, Song JS, Ha H: Reactive oxygen species amplify protein kinase C signaling in high glucose-induced fibronectin expression by human peritoneal mesothelial cells. Kidney Int 2004;65:1170–1179.
[PubMed]
27.
Takahashi S, Taniguchi Y, Nakashima A, Arakawa T, Kawai T, Doi S, Ito T, Masaki T, Kohno N, Yorioka N: Mizoribine suppresses the progression of experimental peritoneal fibrosis in a rat model. Nephron Exp Nephrol 2009;112:e59–e69.
[PubMed]
28.
Bae YS, Lee JH, Choi SH, Kim S, Almazan F, Witztum JL, Miller YI: Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: toll-like receptor 4- and spleen tyrosine kinase-dependent activation of NADPH oxidase 2. Circ Res 2009;104:210–218.
[PubMed]
29.
Fukuoka N, Sugiyama H, Inoue T, Kikumoto Y, Takiue K, Morinaga H, Nakao K, Maeshima Y, Asanuma M, Wang DH, Ogino K, Masuoka N, Makino H: Increased susceptibility to oxidant-mediated tissue injury and peritoneal fibrosis in acatalasemic mice. Am J nephrol 2008;28:661–668.
30.
Noh H, Kim JS, Han KH, Lee GT, Song JS, Chung SH, Jeon JS, Ha H, Lee HB: Oxidative stress during peritoneal dialysis: implications in functional and structural changes in the membrane. Kidney Int 2006;69:2022–2028.
[PubMed]
31.
Bochorakova H, Paulova H, Slanina J, Musil P, Taborska E: Main flavonoids in the root of Scutellaria baicalensis cultivated in Europe and their comparative antiradical properties. Phytother Res 2003;17:640–644.
[PubMed]
32.
Liu LL, Gong LK, Wang H, Xiao Y, Wu XF, Zhang YH, Xue X, Qi XM, Ren J: Baicalin inhibits macrophage activation by lipopolysaccharide and protects mice from endotoxin shock. Biochem Pharmacol 2008;75:914–922.
[PubMed]
33.
Saegusa Y, Sugiyama A, Takahara A, Nagasawa Y, Hashimoto K: Relationship between phosphodiesterase inhibition induced by several Kampo medicines and smooth muscle relaxation of gastrointestinal tract tissues of rats. J Pharmacol Sci 2003;93:62–68.
[PubMed]
34.
Corbel M, Germain N, Lanchou J, Molet S, R e Silva PM, Martins MA, Boichot E, Lagente V: The selective phosphodiesterase 4 inhibitor RP 73–401 reduced matrix metalloproteinase 9 activity and transforming growth factor-β release during acute lung injury in mice: the role of the balance between tumor necrosis factor-α and interleukin-10. J Pharmacol Exp Ther 2002;301:258–265.
[PubMed]
© 2010 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2010
You do not currently have access to this content.
